Self Injection Market Overview
- By 2035, the market is forecasted to abound at USD 181.4 Billion.
- In 2024, the self-injection market size was at USD 60.67 Billion.
- Target market is accelerating at a CAGR of 12.8%.
Self-injection is the act of injecting a drug or other substance into the body. Rising number of patient preference toward self-administration, increasing cases of hormonal diseases & cancer cases, availability of affordable self-injections, ongoing R&D activities, rising healthcare expenditure, rising popularity of home treatment, and others are the factors contributing to the self-injection market growth.
Key Takeaways:
- North America held the largest self-injection market share due to the rising cases of chronic diseases.
- Asia Pacific is expected to be the fastest-growing region in the market due to the growing healthcare sector.
Self Injection Market Drivers & Restraints
Key Drivers of Target Market:
Increasing Cases of Chronic Diseases can Foster Market Diversification
Rising number of chronic diseases can help to expand the self-injection market growth as drug administration by self-injection provides an option to treat chronic inflammatory diseases such as rheumatoid arthritis (RA) and Crohn’s disease (CD). Some medicines used to treat long-term conditions, such as rheumatoid arthritis or Crohn’s disease, are injected under the skin.
- For instance, according to the data published by the National Library of Medicine in January 2024, chronic diseases remain 8 of the 10 leading causes of death in the U.S. Even in the context of COVID-19, heart disease and cancer accounted for nearly 40% of all U.S. deaths in 2022. The estimated cost of chronic disease is expected to reach USD 47 Trillion globally by 2030.
Restraints:
Limitations associated with Self-Injection can Hamper Market Growth
Risk of injection, needle phobia, and incorrect techniques of injections, pain, bruising, or swelling, requirement of periodic training, and psychological impact as some individuals may struggle emotionally with the need to inject themselves regularly, leading to feelings of guilt or inadequacy, and others are the limitations of self-injection, which can impede market growth.
- Counterbalance Statements: One of the major solutions to this problem are comprehensive training and education, use of pre-filled or auto-injectors, improvement of injection sites and techniques, following hygiene and safety protocols, and others.
Opportunities:
New Innovations such as Needle-Free Self-Injectors Surge the Market Growth
Rising demand for needle free self-injections can drive market growth during forecast period as these injectors are initially designed to alleviate needle stick injuries, needle reuse, and cross-contamination, needle-free wash, and others. Needle-free injection techniques can be used to administer vaccines and medications. Needle-free injection offers a fast and effective route of administration.
- For instance, in June 2022, NuGen Medical Devices Inc., a leader in needle-free drug delivery, announced the launch of a new online brand store for its InsuJetTM needle-free injection device. NuGen M.D.’s needle-free injection system for self-administered injections is approved by Health Canada.
Self Injection Market Segmentations & Regional Insights
The market is separated into product, usability, application, end-users, and region.
Product
According to product, the market is classified into needle free injectors, auto injectors, pen injectors, and wearable injectors. Among these, the needle free injectors overcome the market share due to their convenience, safety, and effectiveness.
Usability
The market by usability is segregated into disposable and reusable. The Disposable segment holds the largest Self-injection market share as these type of injectors are convenient, hygienic, and reduce the risk of infection.
- For instance, in May 2021, The Food and Drug Administration (FDA) has approved a single-use, disposable, on-body injector for self-administration of Empaveli (pegcetacoplan). The new Empaveli Injector is designed to offer greater mobility for patients during administration; it is for abdominal subcutaneous use only.
Application
The market by application is dismembered into cancer, autoimmune disorders, hormonal disorders, pain management, and others. Cancer are expected to dominate the target market growth due to rising demand.
End-Users
On the account of end-users, the market is divided into hospital, specialty clinics, and others. Among these, the hospital segment holds the largest share of the market due to their established infrastructure and access to train pharmacists.
Regional
Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America: North America held the largest share of the market owing to the increasing cases of chronic diseases, strong healthcare infrastructure, adoption of advanced technologies, and others.
- For instance, in October 2024, U.S.-based Becton, Dickinson and Company, announced a strategic collaboration with Switzerland-based Ypsomed, a leading developer of injection systems, to advance self-injection solutions for high-viscosity biologic drugs.
Asia Pacific: Asia Pacific is expected to be the fastest growing region of the market due to the growing healthcare sector, high prevalence of chronic diseases, increased awareness regarding self-injection options, and others.
Self-Injection Market Report Scope:
Attribute |
Details |
Market Size 2025 |
USD 69.5 Billion |
Projected Market Size 2035 |
USD 181.4 Billion |
CAGR Growth Rate |
12.8% (2025-2035) |
Base year for estimation |
2024 |
Forecast period |
2025 – 2035 |
Market representation |
Revenue in USD Billion & CAGR from 2024 to 2034 |
Regional scope |
North America - U.S. and Canada Europe – Germany, U.K., France, Russia, Italy, Spain, Netherlands, and Rest of Europe Asia Pacific – China, India, Japan, Australia, Indonesia Malaysia, South Korea, and Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, and Rest of Latin America Middle East & Africa – GCC, Israel, South Africa, and Rest of Middle East & Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segmentation:
By Product:
- Needle Free Injectors
- Auto injectors
- Pen Injectors
- Wearable Injectors
- Others
By Usability:
- Disposable
- Reusable
By Application:
- Cancer
- Autoimmune Disorders,
- Hormonal Disorders
- Pain Management
- Others
By End Users:
- Hospital
- Specialty Clinics
- Others
By Region:
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- Indonesia
- Malaysia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
Self Injection Market Competitive Landscape & Key Players
Many companies operating in the market include BD, YPSOMED, West Pharmaceutical Services, Inc., Haselmeier, NuGen Medical Devices, and others. These players are implementing key strategies, such as focusing on new innovations, launching new products, acquisitions & mergers, and others to achieving market growth.
List of Key Players in the Market:
- BD
- YPSOMED
- West Pharmaceutical Services, Inc.
- Haselmeier
- NuGen Medical Devices
- Owen Mumford Limited
- SHL Medical
- PFIZER INC.
- Amgen Inc.
- Insulet Corporation
- Halozyme, Inc.
- Apikos Pharma & Penardo Biotech Pvt. Ltd.
- Hindustan Syringes & Medical Devices Ltd.
- GSK PLC
Self Injection Market Recent News
- In March 2024, according to a recent announcement, the FDA has approved a new single-dose, pre-filled delivery device, named SeflJect injector, to be used for Acthar Gel (repository corticotropin injection; Mallinckrodt), a treatment indicated for various number of chronic and acute inflammatory and autoimmune conditions, including multiple sclerosis (MS).
- In April 2021, Novartis announced that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application for Xolair (omalizumab) prefilled syringe for self-injection in appropriate patients across all approved U.S. indications. 1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria (CIU) and nasal polyps.
Analyst View:
The industry for self-injection market is placed for substantial growth due to rising number of patient preference towards self-administration, increasing cases of hormonal diseases & cancer cases, availability of affordable self-injections, ongoing R&D activities, and others.
More Related Reports
Facial Injectables Market
Injection Pen Market
Needles Market
Needle Coke Market
Cancer or Tumor Profiling Market
Self Injection Market Company Profile
Company Name |
BD |
Headquarter |
Franklin Lakes, New Jersey, U.S. |
CEO |
Tom Polen |
Employee Count (2024) |
75,000 Employees |
Self Injection Market Highlights
FAQs
Self-injection market size was valued at USD 69.5 Billion in 2025 and is expected to reach USD 181.4 Billion by 2035 growing at a CAGR of 12.8%.
The market is segmented into product, usability, application, end-users, and region.
The Market is segmented by region North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa. North America is expected to dominate the market.
The key players operating in the self-injection market include BD, YPSOMED, West Pharmaceutical Services, Inc., Haselmeier, NuGen Medical Devices, Owen Mumford Limited, SHL Medical, PFIZER INC., Amgen Inc., Insulet Corporation, Halozyme, Inc., Apikos Pharma & Penardo Biotech Pvt. Ltd., Hindustan Syringes & Medical Devices Ltd, and GSK PLC.